Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Int131. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Int131 SCHEMBL29404335 | 1.00 | PPARG (1.00) | PPARGCYP3A4 | |
| Int131 SCHEMBL30035369 | 1.00 | PPARG (1.00) | PPARGCYP3A4 | |
| Int131 SCHEMBL635008 | 0.99 | PPARG (0.98) | PPARGCYP3A4 | |
| SCHEMBL24268600 | 0.93 | PPARG (0.87) | PPARGCYP3A4 | |
| SCHEMBL22515346 | 0.93 | PPARG (0.87) | PPARGCYP3A4 | |
| Int131 SCHEMBL634435 | 0.93 | PPARG (0.86) | PPARGCYP3A4 | |
| SCHEMBL22515271 | 0.92 | PPARG (0.84) | PPARGCYP3A4 | |
| SCHEMBL22203939 | 0.91 | PPARG (0.83) | PPARGCYP3A4 | |
| SCHEMBL7996313 | 0.91 | PPARG (0.83) | PPARGCYP3A4 | |
| SCHEMBL25819017 | 0.91 | PPARG (0.82) | PPARGCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 686 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4729635-A2 | DIAGNOSIS AND TREATMENT OF NAFLD AND LIVER FIBROSIS | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| CN-113939288-B | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2025-04-25 | — | — | CN | claimed |
| WO-2025011750-A1 | COMPOUND FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | Université Toulouse III - Paul Sabatier (FR) | 2025-01-16 | — | — | WO | claimed |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-09-12 | — | — | US | claimed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | claimed |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | KADDURAH DAOUK RIMA F (US) | 2023-11-23 | — | — | US | claimed |
| CN-116963740-A | Compositions and methods for treating kidney disease and fibrosis | 麦托吉宁公司 | 2023-10-27 | — | — | CN | claimed |
| US-20230293565-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-09-21 | — | — | US | claimed |
| EP-4243805-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | Gbiotech S.À.R.L. (CH) | 2023-09-20 | — | — | EP | claimed |
| EP-4135691-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-02-22 | — | — | EP | claimed |
| EP-4125838-A1 | AN INSULIN SENSITIZER FOR USE IN THE PREVENTION AND/OR TREATMENT OF THE DAMAGES CAUSED BY RETINAL DETACHMENT | SORBONNE UNIVERSITE (FR) | 2023-02-08 | — | — | EP | claimed |
| WO-2023004138-A1 | AGONISTS OF TYRO3 AS PROTECTION AGAINST PODOCYTE INJURY IN KIDNEY GLOMERULAR DISEASE | DAS BHASKAR (US) | 2023-01-26 | — | — | WO | claimed |
| US-11519034-B2 | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis | GENFIT (FR) | 2022-12-06 | — | — | US | claimed |
| CN-115397412-A | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2022-11-25 | — | — | CN | claimed |
| US-11484530-B2 | Pharmaceutical compositions comprising the PPAR agonist INT-131 and Nrf2 activators | Kahrs, Bjoern Colin (CH) | 2022-11-01 | — | — | US | claimed |
| WO-2022081350-A2 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | DUKE UNIVERSITY (US) | 2022-04-21 | — | — | WO | claimed |
| WO-2022072925-A1 | COMPOSITIONS AND METHODS OF TREATING KIDNEY DISEASE AND FIBROSIS | MITOKININ, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
| WO-2022020967-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | PPARG 431/4885CYP3A4 826/4885 |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PPARG 467/4885CYP3A4 822/4885 |
| US-11484530-B2 | Pharmaceutical compositions comprising the PPAR agonist INT-131 and Nrf2 activators | PPARG, PPARA, PPARD | PPARG 1/4885CYP3A4 361/4885 |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PPARG 431/4885CYP3A4 826/4885 |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | SLC25A20, CPT2, NDUFAB1 | PPARG 567/4885CYP3A4 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.